echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Galite FASN inhibitor TVB-2640 obtained FDA fast track qualification

    Galite FASN inhibitor TVB-2640 obtained FDA fast track qualification

    • Last Update: 2021-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    TVB-2640 is a FASN inhibitor that is expected to become a "first-in-class" and oral FASN inhibitor.


    According to the press release, in the recent randomized, placebo-controlled, phase 2 trial FASCINATE-1, TVB-2640 was proved to be important in NASH in terms of steatosis, inflammation/lipotoxicity, fibrosis, metabolic biomarkers, etc.


    It is worth mentioning that just early this month, Gally's wholly-owned subsidiary Gan Lai Pharmaceutical and Sagimet Biosciences jointly announced that TVB-2640 has achieved good top-line data in the Chinese cohort of randomized, placebo-controlled Phase 2 clinical trials.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.